A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Biogen
With
Denali Therapeutics Inc.
BIIB122 is an investigational central nervous system-penetrant small molecule inhibitor of leucine-rich repeat kinase 2 (LRRK2). Participants who completed the early termination (ET) visit of the study 283PD302 (NCT05418673) would be eligible for screening of this study and if enrolled, these participants are not eligible for the sub studies of 283PD201.
Age
30–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Clinical diagnosis of PD meeting the Movement Disorder Society Clinical Diagnostic Criteria within 2 years of the Screening Visit, inclusive, and at least 30 years of age at the time of diagnosis
Modified Hoehn and Yahr scale stages 1 to 2 (in OFF state), inclusive, at screening
MDS-UPDRS Parts II and III (in OFF state) combined score less than or equal to (≤)50 at screening
You may not be if
Clinically significant neurological disorder other than PD, including but not limited to stroke, dementia, or seizure, within 5 years of screening visit, in the opinion of the Investigator
Clinical evidence of atypical parkinsonism (e.g., multiple-system atrophy or progressive supranuclear palsy) or evidence of drug-induced parkinsonism.
Montreal Cognitive Assessment (MoCA) score \<24 at the screening visit.
Clareo Health | A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80
